{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:50:26Z","timestamp":1778611826418,"version":"3.51.4"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/ftd.0b013e318280d0ad","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T21:43:58Z","timestamp":1363988638000},"page":"209-216","source":"Crossref","is-referenced-by-count":14,"title":["Discordant Associations Between SLCO1B1 521T\u2192C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146"],"prefix":"10.1097","volume":"35","author":[{"given":"Xinyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camlin","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"DiFrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Dykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":". HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":". The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.","volume":"101","author":"Kim","year":"1998","journal-title":"J Clin Invest"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FPC.0b013e328335b02d","article-title":". HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.","volume":"20","author":"Hartkoorn","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":". CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R5-9-20210129","first-page":"754","article-title":". Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.","volume":"29","author":"Huang","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1124\/dmd.107.018689","article-title":". Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.","volume":"36","author":"Gupta","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"33309","DOI":"10.1074\/jbc.C100375200","article-title":". Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.","volume":"276","author":"Dussault","year":"2001","journal-title":"J Biol Chem"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/14622416.8.7.787","article-title":"Role of OATP transporters in the disposition of drugs.","volume":"8","author":"Niemi","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FPC.0b013e328336eee4","article-title":". ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.","volume":"20","author":"Lubomirov","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2125.2009.03551.x","article-title":". The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.","volume":"69","author":"Kohlrausch","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/FTD.0b013e318225384f","article-title":". CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavirritonavir in HIV-infected children.","volume":"33","author":"Rakhmanina","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","article-title":". Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":". Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":". The genetic determinants of the CYP3A5 polymorphism.","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkp317","article-title":". Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.","volume":"64","author":"Anderson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.qai.0000225013.53568.69","article-title":". Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.","volume":"42","author":"Anderson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2125.2007.02903.x","article-title":". Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.","volume":"64","author":"Solas","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.clpt.2005.08.014","article-title":". Variation in oral clearance of saquinavir is predicted by CYP3A51 genotype but not by enterocyte content of cytochrome P450 3A5.","volume":"78","author":"Mouly","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/FPC.0b013e32834e1641","article-title":". The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.","volume":"22","author":"Birdwell","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":". Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/00912709922012006","article-title":"The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.","volume":"39","author":"Yu","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CPP38069","article-title":"P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.","volume":"38","author":"Fromm","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2125.2002.01591.x","article-title":". MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.","volume":"53","author":"Drescher","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/135965350400900610","article-title":". Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.","volume":"9","author":"Zhu","year":"2004","journal-title":"Antivir Ther"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/499056","article-title":". Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C--T polymorphism at the multidrug resistance gene 1.","volume":"42","author":"Rodriguez","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2125.2002.01691.x","article-title":". MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.","volume":"54","author":"Gerloff","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0009-9236(03)00234-0","article-title":". No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.","volume":"74","author":"Pauli-Magnus","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2125.2004.02182.x","article-title":". MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.","volume":"58","author":"Mai","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":". Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz andor nelfinavir: an Adult Aids Clinical Trials Group study.","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/87912","article-title":"The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.","volume":"7","author":"Synold","year":"2001","journal-title":"Nat Med"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/mp9000298","article-title":"Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.","volume":"6","author":"Meyer zu Schwabedissen","year":"2009","journal-title":"Mol Pharmacol"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"38379","DOI":"10.1074\/jbc.M404949200","article-title":". The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR).","volume":"279","author":"Burk","year":"2004","journal-title":"J Biol Chem"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/dmd.107.016600","article-title":". Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptorNR1I2 and their association with CYP3A4 expression.","volume":"36","author":"Lamba","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/QAD.0b013e32831f9148","article-title":". A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.","volume":"23","author":"Demeter","year":"2009","journal-title":"AIDS"},{"key":"R36-9-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1310\/MUQC-QXBC-8118-BPM5","article-title":". A multi-investigatorinstitutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.","volume":"4","author":"Haas","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R39-9-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"R40-9-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FPC.0b013e328333b99c","article-title":". PharmGKB very important pharmacogene: SLCO1B1.","volume":"20","author":"Oshiro","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R41-9-20210129","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":". Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R42-9-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clpt.2005.07.003","article-title":". Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.","volume":"78","author":"Chung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R43-9-20210129","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":". SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R44-9-20210129","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":". Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R45-9-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":". Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R46-9-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2005.01.018","article-title":". Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.","volume":"77","author":"Niemi","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R47-9-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clpt.2005.11.003","article-title":". Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.","volume":"79","author":"Katz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R48-9-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.fpc.0000230420.05221.71","article-title":". Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients.","volume":"16","author":"Xiang","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R49-9-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchromb.2005.10.034","article-title":". A LC-MSMS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1.","volume":"830","author":"Oswald","year":"2006","journal-title":"J Chromatogr B"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318280d0ad","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T21:40:33Z","timestamp":1715118033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201304000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318280d0ad","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}